ReliantHeart HeartAssist5(R) VAD achieves CE Mark for European distribution

ReliantHeart HeartAssist5(R) VAD achieves CE Mark for European distribution

HOUSTON, Texas, Nov. 10, 2013 (GLOBE NEWSWIRE) -- via PRWEB - The ReliantHeart
HeartAssist 5®Ventricular Assist Device (VAD) has been CE Mark* approved in
Europe for use in patients requiring ventricular support due to end stage
heart failure. The HeartAssist 5® is approved for bridge to transplant (BTT)
patients awaiting cardiac transplantation and for destination therapy (DT)
patients who are not candidates for cardiac transplantation.

The CE Mark for the HeartAssist 5® was previously granted to MicroMed
Technology, Inc. and was first available for European distribution in 2009.
Through completion of a court approved transaction, ReliantHeart, Inc. has
become the successor-in-interest to the assets of MicroMed Technology, Inc.,
and will manufacture, sell and support the HeartAssist5® and its suite of VAD
products and accessories.

An amendment to the earlier CE mark was granted October of 2012 to allow
around the clock remote monitoring with the HeartAssist5® Conquest
Controller™, a lightweight wearable controller designed to collect critical
flow data. That data, as well as speed and power measurements, are transmitted
to caregivers through the exclusive HeartAssist5® Remote Monitoring System.
The HeartAssist5® is the only remotely monitored VAD in the world.

ReliantHeart competes in Europe with two companies: Thoratec (THOR) and
HeartWare (HTWR). On November 6, 2013, HeartWare announced strong third
quarter results of a 140% increase over same period last year. Revenue from
international markets, generated through the sale of 287 units, was $26.6
million, an increase of approximately 38% from $19.3 million in the third
quarter of 2012.

ReliantHeart intends to enter the U.S. market through an IDE (Investigational
Device Exemption), which will allow the HeartAssist5® to be sold for use in a
clinical trial approved by the FDA to collect safety and effectiveness data.

*The European Union applies the CE (Conformité Européenne) Marking process to
ensure patient/user safety and to enforce that the manufacturer's device
fulfills what it is designed to perform.

This article was originally distributed on PRWeb. For the original version
including any supplementary images or video, visit
http://www.prweb.com/releases/2013/11/prweb11315432.htm

CONTACT: ReliantHeart, Inc.
         Sailesh Saxena
         ssaxena@reliantheart.com
         713-457-1480